A Phase 1 Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]MK-1084 in Healthy Adult Participants
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs MK-1084 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 21 Nov 2024 New trial record